VACTHERA BIOTECH
Vacthera is a biotechnology company developing influenza virus based vaccines and cancer immuno therapies Their platform technology enables the generation of stable influenza virus vaccine vectors that can be produced at high yields. They focus on two areas:
VACTHERA BIOTECH
Industry:
Biotechnology Health Care
Founded:
2016-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.vacthera.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Acambis
Acambis is a biotechnology company developing vaccines to treat infectious diseases in Europe and North America.
Alethia BioTherapeutics
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Mucosis
Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.
Virttu Biologics
Virttu is a privately held biotechnology company, which has pioneered the development of oncolytic viruses for treating cancer.
More informations about "Vacthera BioTech"
Vacthera BioTech - Crunchbase Company Profile & Funding
Vacthera is a biotechnology company developing influenza virus based vaccines and cancer immuno therapies Their platform technology enables the generation of stable influenza virus …See details»
Could these new flu vaccines prevent deaths from deadly outbreaks?
From threat to cure: understanding of virus-induced cell death …
Jun 11, 2020 · In this review we give a summary of efforts undertaken to develop oncolytic influenza A viruses. We discuss strategies for targeting viral replication to cancerous lesions …See details»
Vacthera BioTech GmbH - Drug pipelines, Patents, Clinical trials
Explore Vacthera BioTech GmbH with its drug pipeline, therapeutic area, technology platform, .See details»
Vacthera GmbH, Austria - Oncolytic Influenza Virus
Vacthera’s candidate OncoFluVec (VTH202) is an optimized oncolytic influenza virus to be used in the clinic. It offers the following value proposition: High treatment efficacy due to inherent …See details»
reposiTUm: Vacthera BioTech : business plan for a Biotech startup …
Vacthera is a biotechnology company developing influenza virus based vaccines and cancer immunotherapies. Vacthera¿s patented platform technology allows genetic modification of the …See details»
Vacthera BioTech GmbH - BioCentury Company Profiles - BCIQ
Jul 25, 2019 · Vacthera BioTech GmbH - BioCentury Company Profiles for the biopharma industrySee details»
Vacthera BioTech GmbH, Wien, Österreich - North Data
Vacthera BioTech GmbH, Wien, Österreich, Firmenbuch 450026d: Bilanzsumme, Gewinn, Umsatz, Netzwerk, WirtschaftsinfosSee details»
Vacthera BioTech - Crunchbase
Vacthera is a biotechnology company developing influenza virus based vaccines and cancer immuno therapiesSee details»
Vacthera BioTech - Tech Stack, Apps, Patents & Trademarks
Vacthera is a biotechnology company developing influenza virus based vaccines and cancer immuno therapiesSee details»
Vacthera - Forbes Start-Up-Challenge
Nov 3, 2017 · Vacthera möchte eine universale Grippeimpfung, die nicht jedes Jahr neu produziert werden muss, entwickeln. So sollen Impfungen bis zu fünf Jahre wirksam sein.See details»
Dr Andrei Egorov | Emerging Disease Vaccines - terrapinn.com
Since 2012 Egorov is a founder and CSO of an Austrian startup company developing attenuated influenza vaccine vectors. Dr Andrei Egorov - The meeting place for vaccine professionals …See details»
Turbocharging Vaccines: Emerging Adjuvants for Dendritic Cell …
Vacthera is developing a modified oncolytic strain of influenza, OncoFluVec, as tumor virotherapy. Future clinical trials are awaited to determine the viability of using flu virus for treating cancers.See details»
Andrej Egorov | Vacthera BioTech GmbH | Austria - OMICS …
Dr. Andrej Egorov received his MD and PhD in St. Petersburg, Russia. The initial topic of his carrier was the research and development of the live cold-adapted attenuated influenza …See details»
Curriculum Vitae BERGMANN Michael Personal Data
2015 Founder, Vacthera Ges.m.b.H, Vienna, www.vacthera.com 2002 – 2007 Consultant, Avir Green Hills Biotechnology, Vienna Awards 2017 Best of Biotech, AWS, Vienna 2017 Poster …See details»
BACTHERA
Bacthera Denmark A/S Kogle Allé 6 2970 Hørsholm Denmark CVR no. 40697322 ; Bacthera AG Hochbergerstrasse 60A 4057 Basel Switzerland CHE-361.886.435 MWSTSee details»
Organization | Veterans Affairs Canada
Delivering benefits and services and for providing social and economic support that respond to the needs of Veterans, our other clients and their families. This branch is responsible for: Policy …See details»
Hydrocarbon-degrading bacteria in Colombia: systematic review
Mar 2, 2022 · We found that 2018 was the year with the largest number of publications in Colombia, and most frequently identified bacterial genera were Pseudomonas and Bacillus. …See details»
NATO Enhanced Forward Presence - Wikipedia
The coat of arms of the Enhanced Forward Presence. Enhanced Forward Presence (EFP) is a NATO-allied forward-deployed defense and deterrence military force in Northern, Central and …See details»
VACTERL Network | Sharing Similarities ♥ Celebrating Differences
The VACTERL Network was established to provide support to families who have a child born with VACTERL/VATER or adults with VACTERL. The purpose of our organization is to share …See details»